BioIntelliSense’s wearable BioSticker will soon be used to gather data in clinical trials with cancer patients. To that end, the company has formed a strategic partnership with The Leukemia & Lymphoma Society (LLS), which will be using the stickers to monitor the vital signs of the hematological cancer patients in the study.
The BioIntelliSense BioSticker is an FDA-approved single-use device that can be worn on the body for a period of up to 30 days. The data collected with the device can be consolidated and analyzed using the company’s Data-as-a-Service platform, which will also be provided to LLS through the new strategic partnership.
LLS will use the data generated with the BioSticker to gauge the effectiveness of different treatments, linking those treatments to a patient’s symptoms to see how well they respond. The BioSticker is able to track a number of different metrics, including body temperature, heart rate, respiration, and body position.
“Our medical grade devices and data services can have a profound impact on oncology care by unlocking unique and actionable clinical intelligence to guide treatment decisions,” said BioIntelliSense CEO James Mault. “We are extremely proud to be partnering with The Leukemia & Lymphoma Society as a global leader in blood cancer research and support services.”
The BioSticker received FDA approval and was cleared for commercial launch in January of 2020, shortly ahead of the international spread of COVID-19. The pandemic generated much more interest in remote patient monitoring solutions that can provide doctors with accurate medical data while minimizing the need for in-person contact.
BioIntelliSense has since supplemented the BioSticker with the release of a 5G BioHub that will automatically consolidate patient data and upload that data to the cloud. The company also updated its Data-as-a-Service platform to better track common symptoms like sneezing and coughing in real time.